Drug eluting balloons.

Ever since the first percutaneous transluminal angioplasty (PTA) was carried out in Switzerland in 1977, restenosis remains a major drawback of this minimally invasive treatment intervention. Numerous attempts to increase vessel patency after PTA have included systemic medications and endovascular brachytherapy, but these techniques have not met our expectations in preventing restenosis. Nitinol stents have been shown to reduce rates of restenosis and target lesion revascularization in patients undergoing endovascular treatment of long femoropopliteal obstructions. Despite further technical refinements in nitinol stent technology, restenosis occurs in approximately every third patient undergoing femoropopliteal stenting. Similarly, initial clinical trials with drug-eluting stents have failed to indicate restenosis inhibition in femoropopliteal segment. Unfortunately, restenosis rates after below-the-knee PTA and stenting have been reported to be even higher than those following femoropopliteal revascularization. Current concepts for the prevention and treatment of restenosis after PTA or stenting include the sustained release of antiproliferative paclitaxel into the vessel wall. Drug eluting balloons are a promising, novel technology aimed at inhibiting restenosis after PTA. Its clinical efficacy in reducing restenosis has already been proven for coronary arteries as well as for the femoropopliteal segment. The purpose of this article is to review the clinical utility of drug-eluting balloons for lower limb endovascular interventions.

[1]  Johannes Lammer,et al.  Sustained Benefit at 2 Years of Primary Femoropopliteal Stenting Compared With Balloon Angioplasty With Optional Stenting , 2007, Circulation.

[2]  K. Johnston Femoral and popliteal arteries: reanalysis of results of balloon angioplasty. , 1992, Radiology.

[3]  F. Eberli,et al.  Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.

[4]  John V. White,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[5]  D. Karnabatidis,et al.  Sirolimus-Eluting versus Bare Stents after Suboptimal Infrapopliteal Angioplasty for Critical Limb Ischemia: Enduring 1-Year Angiographic and Clinical Benefit , 2007, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[6]  C. Claussen,et al.  Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. , 2008, The New England journal of medicine.

[7]  Sanjay Shrivastava,et al.  Fracture of self-expanding nitinol stents stressed in vitro under simulated intravascular conditions. , 2008, Journal of vascular surgery.

[8]  B. Hamm,et al.  Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial , 2008, Circulation.

[9]  Christopher Piorkowski,et al.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting. , 2005, Journal of the American College of Cardiology.

[10]  M. Böhm,et al.  Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis , 2004, Circulation.

[11]  R. Pötter,et al.  Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty: pilot study. , 1998, Radiology.

[12]  Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery , 2006 .

[13]  Thomas Zeller,et al.  Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. , 2005, Journal of vascular and interventional radiology : JVIR.